Clinical trials for severe sepsis. Past failures, and future hopes

Area of Science:

• Critical care medicine
• Immunology
• Clinical trial design

Background:

• Severe sepsis and septic shock remain leading causes of mortality worldwide.
• Despite extensive research, immunotherapeutic agents have shown limited success in clinical settings.
• Preclinical studies often suggest significant benefits that do not translate to human trials.

Purpose of the Study:

• To review the therapeutic rationale behind immunotherapies for sepsis.
• To analyze preclinical evaluation methods for sepsis treatments.
• To examine clinical trial designs of past innovative sepsis therapies.

Main Methods:

• Literature review of published clinical trials for severe sepsis and septic shock.
• Analysis of preclinical data and therapeutic strategies for immunotherapies.
• Evaluation of clinical trial designs, including patient selection and outcome measures.

Main Results:

• Numerous immunotherapeutic agents have failed to demonstrate efficacy in severe sepsis and septic shock.
• Discrepancies between preclinical promise and clinical outcomes are common.
• Past clinical trial designs may have contributed to the observed failures.

Conclusions:

• Past failures highlight critical gaps in our understanding of sepsis pathophysiology and treatment response.
• Lessons learned from previous immunotherapeutic trials are essential for future drug development.
• Improved preclinical models and refined clinical trial designs are necessary for advancing sepsis treatment.